RDInvesting Provides Investors with Free In-Depth Equity Reports on ANIP, CERN, CVS and ISIS


Follow this company

Companies Mentioned

NASDAQ:ANIP / NASDAQ:CERN / NYSE:CVS / NASDAQ:ISIS
01/24/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

ANI Pharmaceuticals Inc. (NASDAQ: ANIP) shares declined 2.44 percent to close at $22.78 a share Thursday. The stock traded between $21.93 and $23.68 on volume of 176,985 shares traded. Analysts at Oppenheimer have recently initiated coverage on the company with an "outperform" rating. Shares of ANI Pharmaceuticals have gained approximately 13.0 percent year-to-date.

Find out more about ANI Pharmaceuticals including full access to the free equity report at:       
www.RDInvesting.com/ANIP

Cerner Corporation (NASDAQ: CERN) shares declined 0.93 percent to close at $56.49 a share Thursday. The stock traded between $55.85 and $57.21 on volume of 1.12 million shares traded. Analysts at ISI Group have recently upgraded the company’s rating to "strong buy" from "neutral". Shares of Cerner have gained approximately 39.0 percent in the past year.

Find out more about Cerner including full access to the free equity report at:     
www.RDInvesting.com/CERN

CVS Caremark Corporation (NYSE: CVS) shares declined 1.01 percent to close at $68.47 a share Thursday. The stock traded between $68.10 and $68.78 on volume of 5.63 million shares traded. Analysts at ISI Group have recently upgraded the company’s rating to "strong buy" from "buy". Shares of CVS Caremark have gained approximately 30.0 percent in the past year.

Find out more about CVS Caremark including full access to the free equity report at:       
www.RDInvesting.com/CVS

ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) shares declined 1.53 percent to close at $50.17 a share Thursday. The stock traded between $49.35 and $50.60 on volume of 1.0 million shares traded. Analysts at Deutsche Bank have recently initiated coverage on the company with a "buy" rating. Shares of ISIS Pharmaceuticals have gained approximately 250.0 percent in the past year.

Find out more about ISIS Pharmaceuticals including full access to the free equity report at:     
www.RDInvesting.com/ISIS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:                   
Research Driven Investing         
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *